Latest Pharma Insights
FastWave’s Artero Enters Pivotal Trial, Betting Speed And Simplicity Can Crack A Crowding IVL Market
With FDA clearance for its SPARC pivotal trial, CEO Scott Nelson is betting that a physician-first design—circumferential energy, a faster pulse, and a workflow built for office-based labs—can set the Artero electric IVL system apart from a field of deep-pocketed rivals.
Medtech Insight - August 24, 2026
With FDA clearance for its SPARC pivotal trial, CEO Scott Nelson is betting that a physician-first design—circumferential energy, a faster pulse, and a workflow built for office-based labs—can set the Artero electric IVL system apart from a field of deep-pocketed rivals.
Medtech Insight - August 24, 2026
FDA Device Recalls: Records Jumped 28% In 2026, But Distinct Events Barely Moved
A 28% jump in FDA device recall records in 2026 looks alarming - unless you count distinct events, which rose just 2.5%, while Class I events actually fell 16%. Two firms, Medline and Olympus, and the way kitted products are counted explain most of the surge.
Medtech Insight - August 24, 2026
A 28% jump in FDA device recall records in 2026 looks alarming - unless you count distinct events, which rose just 2.5%, while Class I events actually fell 16%. Two firms, Medline and Olympus, and the way kitted products are counted explain most of the surge.
Medtech Insight - August 24, 2026
Three Strategies US Device Makers Are Using To Stem Staff Burnout And Turnover
Corporate medtech industry employee engagement has slipped to a decade low. In 2026, leading medtech firms abandoned generic HR programs in favor of mission-linked leadership, adaptive capacity building and authentic manager communication to stem staff burnout and turnover.
In Vivo - August 24, 2026
Corporate medtech industry employee engagement has slipped to a decade low. In 2026, leading medtech firms abandoned generic HR programs in favor of mission-linked leadership, adaptive capacity building and authentic manager communication to stem staff burnout and turnover.
In Vivo - August 24, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: melanoma win for Moderna's mRNA candidate; lung cancer victory for Enhertu; measuring industry R&D productivity; Enveda's post-GLP-1 contender; and the factors behind China's rise.
Scrip - August 24, 2026
In this week's episode: melanoma win for Moderna's mRNA candidate; lung cancer victory for Enhertu; measuring industry R&D productivity; Enveda's post-GLP-1 contender; and the factors behind China's rise.
Scrip - August 24, 2026
Pinworm Treatment Marketer Scratches Claims For Efficacy Against Other Intestinal Parasites
Wellspring Meds discontinues express claims for Pin Rid challenged by PinWorm marketer Reese Consumer Health but maintains claims to also treat roundworms, hookworms, whipworms, threadworms and tapeworms are accurate.
HBW Insight - August 24, 2026
Wellspring Meds discontinues express claims for Pin Rid challenged by PinWorm marketer Reese Consumer Health but maintains claims to also treat roundworms, hookworms, whipworms, threadworms and tapeworms are accurate.
HBW Insight - August 24, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: melanoma win for Moderna's mRNA candidate; lung cancer victory for Enhertu; measuring industry R&D productivity; Enveda's post-GLP-1 contender; and the factors behind China's rise.
Scrip - August 24, 2026
In this week's episode: melanoma win for Moderna's mRNA candidate; lung cancer victory for Enhertu; measuring industry R&D productivity; Enveda's post-GLP-1 contender; and the factors behind China's rise.
Scrip - August 24, 2026
FastWave’s Artero Enters Pivotal Trial, Betting Speed And Simplicity Can Crack A Crowding IVL Market
With FDA clearance for its SPARC pivotal trial, CEO Scott Nelson is betting that a physician-first design—circumferential energy, a faster pulse, and a workflow built for office-based labs—can set the Artero electric IVL system apart from a field of deep-pocketed rivals.
Medtech Insight - August 24, 2026
With FDA clearance for its SPARC pivotal trial, CEO Scott Nelson is betting that a physician-first design—circumferential energy, a faster pulse, and a workflow built for office-based labs—can set the Artero electric IVL system apart from a field of deep-pocketed rivals.
Medtech Insight - August 24, 2026
FDA Device Recalls: Records Jumped 28% In 2026, But Distinct Events Barely Moved
A 28% jump in FDA device recall records in 2026 looks alarming - unless you count distinct events, which rose just 2.5%, while Class I events actually fell 16%. Two firms, Medline and Olympus, and the way kitted products are counted explain most of the surge.
Medtech Insight - August 24, 2026
A 28% jump in FDA device recall records in 2026 looks alarming - unless you count distinct events, which rose just 2.5%, while Class I events actually fell 16%. Two firms, Medline and Olympus, and the way kitted products are counted explain most of the surge.
Medtech Insight - August 24, 2026
Pinworm Treatment Marketer Scratches Claims For Efficacy Against Other Intestinal Parasites
Wellspring Meds discontinues express claims for Pin Rid challenged by PinWorm marketer Reese Consumer Health but maintains claims to also treat roundworms, hookworms, whipworms, threadworms and tapeworms are accurate.
HBW Insight - August 24, 2026
Wellspring Meds discontinues express claims for Pin Rid challenged by PinWorm marketer Reese Consumer Health but maintains claims to also treat roundworms, hookworms, whipworms, threadworms and tapeworms are accurate.
HBW Insight - August 24, 2026
Silo Locks Down IP Rights For PTSD Asset As It Prepares 505(b)(2) Filing
?In a bid to shorten clinical timelines and reduce costs, Silo Pharma plans to use?the?Food and Drug Administration’s streamlined 505(b)(2) regulatory pathway to push forward with its PTSD treatment.? Meanwhile a Canadian patent has been granted following hot on the heels of a European patent.
Generics Bulletin - August 21, 2026
?In a bid to shorten clinical timelines and reduce costs, Silo Pharma plans to use?the?Food and Drug Administration’s streamlined 505(b)(2) regulatory pathway to push forward with its PTSD treatment.? Meanwhile a Canadian patent has been granted following hot on the heels of a European patent.
Generics Bulletin - August 21, 2026
Richter Sees GenMed Recovery Stretching Into 2027
Richter expects its General Medicines business to return to mid-single-digit growth from 2027, with newer generics helping offset legacy-product erosion, distributor changes and market-specific setbacks that weighed on first-half performance.
Generics Bulletin - August 21, 2026
Richter expects its General Medicines business to return to mid-single-digit growth from 2027, with newer generics helping offset legacy-product erosion, distributor changes and market-specific setbacks that weighed on first-half performance.
Generics Bulletin - August 21, 2026
Glenmark Builds On US Respiratory Portfolio With Generic Flonase Nasal Spray Approval
The latest FDA approval of a fluticasone propionate nasal spray further secures Glenmark’s ambition to resurrect its US presence with an expansive respiratory product portfolio.
Generics Bulletin - August 21, 2026
The latest FDA approval of a fluticasone propionate nasal spray further secures Glenmark’s ambition to resurrect its US presence with an expansive respiratory product portfolio.
Generics Bulletin - August 21, 2026
Sawai Launches Four First-Time Generics As Revenue Rises But Profit Falls In Q1
Sawai Pharmaceuticals records early revenue growth but falling operating profit in its first-quarter earnings report for a new fiscal year.
Generics Bulletin - August 21, 2026
Sawai Pharmaceuticals records early revenue growth but falling operating profit in its first-quarter earnings report for a new fiscal year.
Generics Bulletin - August 21, 2026
Three Strategies US Device Makers Are Using To Stem Staff Burnout And Turnover
Corporate medtech industry employee engagement has slipped to a decade low. In 2026, leading medtech firms abandoned generic HR programs in favor of mission-linked leadership, adaptive capacity building and authentic manager communication to stem staff burnout and turnover.
In Vivo - August 24, 2026
Corporate medtech industry employee engagement has slipped to a decade low. In 2026, leading medtech firms abandoned generic HR programs in favor of mission-linked leadership, adaptive capacity building and authentic manager communication to stem staff burnout and turnover.
In Vivo - August 24, 2026